Radioimmunodetection of cancer with monoclonal antibodies: Current status, problems, and future directions

Murray, James L.; Unger, Michael; Halpern, Samuel E.

doi:10.1016/s1040-8428(88)80017-9

Cited by 9 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies can be labeled with a gamma-emitting radioisotope, administered intravenously, intralymphatically, intratumorally, or intracavitarily, 77 and the body scanned with a gamma camera to detect the localization of the isotope in presumed tumor-bearing sites [100]. Any objective assessment of this use for monoclonal antibodies must conclude that this is a major area of promise unfulfilled.…”

Section: Tumor Imaging and Stagingmentioning

confidence: 99%

Biological response modifiers in the management of patients with breast cancer

Longo

Hartmann

1990

Breast Cancer Res Tr

View full text Add to dashboard Cite

Despite impressive progress in understanding the biology of breast cancer, mechanisms of host defense, and the pathophysiology of the metastatic process, this burgeoning fact bank has made little impact on the management of patients with breast cancer. There are many interesting ideas for improved diagnosis and therapy in various stages of development, but few have actually translated into improved survival of patients with breast cancer. Potentially useful biological agents include cytokines, monoclonal antibodies, immunotoxins, vaccines, and adoptive cellular therapies. Therapies targetting growth factor receptors and the cellular machinery required for metastasis may become useful, especially when used in combination with other cytotoxic agents. Colony-stimulating factors may allow a test of the hypothesis that augmented dose-intensity of cytotoxic chemotherapy will cure more patients. Though we are not yet sure precisely how to use all of these new tools, there can be little doubt that their application will make a significant impact on the management of patients with breast cancer and other malignancies in the next decade.

show abstract

Section: Tumor Imaging and Stagingmentioning

confidence: 99%

Biological response modifiers in the management of patients with breast cancer

Longo

Hartmann

1990

Breast Cancer Res Tr

View full text Add to dashboard Cite

show abstract

“…Besides the important role of murine monoclonal antibodies (MAbs) in basic research and in vitro diagnosis, they became important tools for in vivo diagnosis of tumours (Murray & Unger, 1988), inflammatory processes (Joseph et al, 1988) and thrombosis (Haber et al, 1990). Furthermore it was clinically proven that murine MAbs inhibit transplantation rejection (Goldstein, 1987;Kurrle et al, 1988) and interfere with gram negative sepsis (Greenman et al, 1991).…”

mentioning

confidence: 99%